[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556875":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":10,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":10},{"fullName":5,"class":6},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"First-line treatment for advanced stage",null,"Any first-line regiment including Adebrelimab for advanced stage ES-SCLC",[13],"Drug: First-line Adebrelimab regiment for advanced stage ES-SCLC",{"label":15,"type":10,"description":16,"interventionNames":17},"Second-line and beyond for advanced stage","Any Second- or later-line and regiment including Adebrelimab for advanced stage ES-SCLC",[18],"Drug: Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","First-line Adebrelimab regiment for advanced stage ES-SCLC","First-line Adebrelimab in any regiment for advanced stage ES-SCLC",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC","Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC",[15],[30],{"name":31,"affiliation":5,"role":32},"Shengxiang Ren, MD.","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Keyi Jia, MD.PHD.","CONTACT","+86 17621199707","jekyll_1206@163.com",{"name":40,"role":36,"phone":41,"phoneExt":10,"email":42},"Libo Luo, MD.Master.","+86 15087789662","luolibo@tongji.edu.cn",{"type":32,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Ren Shengxiang","Prof.","100556875","a-multicenter-real-world-cohort-study-of-adebrelimab-injection-in-the-treatment-of-extensive-stage-small-cell-lung-cancer-100556875",false,"NCT06530797","A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Patients must meet all of the following criteria to be eligible for inclusion in this study:\n\n  1. Voluntarily sign the informed consent form and agree to participate in the study.\n  2. Histopathologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).\n  3. Age ≥ 18 years.\n  4. Determined by the investigator to be eligible for Adebrelimab treatment.\n\nExclusion Criteria:\n\n* Patients with any of the following conditions are not eligible for inclusion in this study:\n\n  1. Evidence of being a pregnant or lactating female.\n  2. Currently receiving treatment as part of a blinded study protocol.\n  3. Any other condition that the investigator deems unsuitable for inclusion in the study.","ALL","18 Years",{"count":55,"type":56},2000,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to evaluate the safety and efficacy of Adebrelimab Injection in extensive-stage small cell lung cancer (ES-SCLC) under real-world conditions. Specifically, the study aims to assess the treatment of Adebrelimab Injection across various subgroups of ES-SCLC patients. The goal is to provide information on treatment patterns and effectiveness in real-life settings, explore potential predictive or prognostic biomarkers, and preliminarily evaluate the pharmacoeconomic indicators of Adebrelimab Injection treatment for extensive-stage small cell lung cancer.",[60],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)",[62,63],"Extensive-stage small cell lung cancer (ES-SCLC)","Adebrelimab","NOT_YET_RECRUITING","2024-07-26",{"date":67,"type":68},"2024-07-31","ACTUAL",{"date":70,"type":56},"2024-08-01",{"date":72,"type":56},"2026-09-01",{"name":5,"class":6}]